简介：The results of the Lonestar Trial are set to be presented in this year’s APASL. Using a once daily， fixed-dose combination of sofosbuvir (SOF) and ledipasvir (LDV)， the team treated 100 patients to test the necessity of adding ribavirin (RBV) to the regimen. Results suggest a 97% sustained-virological response (SVR)， regardless of the addition of ribavirin.